Abstract: A cardiac pacing system that includes an implantable pulse generator and electrical leads that include a lead body portion having a distal end and a proximal end, a connector configured to electrically connect the proximal end of the lead body to the pulse generator, and at least one electrode disposed at the distal end of the lead body for delivering electrical stimulation to a patient's heart, wherein the distal end of the lead body is configured to terminate within the mediastinum of the thoracic cavity of the patient, proximate to the heart.

Abstract: A cardiac pacing system that includes an implantable pulse generator and electrical leads that include a lead body portion having a distal end and a proximal end, a connector configured to electrically connect the proximal end of the lead body to the pulse generator, and at least one electrode disposed at the distal end of the lead body for delivering electrical stimulation to a patient's heart, wherein the distal end of the lead body is configured to terminate within the mediastinum of the thoracic cavity of the patient, proximate to the heart.

Abstract: A cardiac pacing system that includes an implantable pulse generator and electrical leads that include a lead body portion having a distal end and a proximal end, a connector configured to electrically connect the proximal end of the lead body to the pulse generator, and at least one electrode disposed at the distal end of the lead body for delivering electrical stimulation to a patient's heart, wherein the distal end of the lead body is configured to terminate within the mediastinum of the thoracic cavity of the patient, proximate to the heart.

Abstract: A medical device includes an expandable element for location in a blood vessel. The expandable element is movable between a collapsed configuration and an expanded configuration. In the expanded configuration, at least a part of a longitudinal axis of the expandable element is curved in three-dimensional space. The medical device can be stent deployment device which includes an elongate catheter shaft and an inflatable balloon.

Abstract: A stent deployment device comprises an elongate catheter shaft (2), and an inflatable balloon (3). The inflatable balloon (3) is movable between a collapsed configuration and an expanded configuration. In the expanded configuration part of the longitudinal axis of the balloon (3) is curved in three-dimensional space, and part of the balloon (3) is helically shaped. A stent (6) is movable from a collapsed delivery configuration to a partially expanded intermediate configuration, and subsequently from the intermediate configuration to a fully expanded deployed configuration. In the delivery configuration the longitudinal axis of the stent (6) is straight. The longitudinal axis of the stent (6) may be straight or curved in three-dimensional space in the intermediate configuration. In the deployed configuration the longitudinal axis of the stent (6) is curved in three-dimensional space. The balloon (3) in the expanded configuration exerts force on the stent (6).

Abstract: A stent (1) for deployment in a blood vessel which is movable between an unloaded straight cylindrical state and a loaded curved state. The stent (1) is bendable between a first loaded configuration when the blood vessel is in the unloaded state, and a second loaded configuration when the blood vessel is in the loaded state. The stent (1) has an unloaded configuration which is intermediate the first loaded configuration and the second loaded configuration. Because of the unloaded configuration of the stent (1), the degrees of deformation which the stent (1) undergoes are minimized leading to minimized strains, increased fatigue life, and reduced risk of fracture.

Abstract: A cardiac pacing system that includes an implantable pulse generator and electrical leads that include a lead body portion having a distal end and a proximal end, a connector configured to electrically connect the proximal end of the lead body to the pulse generator, and at least one electrode disposed at the distal end of the lead body for delivering electrical stimulation to a patient's heart, wherein the distal end of the lead body is configured to terminate within the mediastinum of the thoracic cavity of the patient, proximate to the heart.

Abstract: A medical device suitable for location in a body lumen is movable between a first loaded configuration and a second loaded configuration. The device has an unloaded configuration which is intermediate the first loaded configuration and the second loaded configuration. The device can be a stent for deployment in a blood vessel.

Abstract: A medical device suitable for location in a body lumen is movable between a first loaded configuration and a second loaded configuration. The device has an unloaded configuration which is intermediate the first loaded configuration and the second loaded configuration. The device can be a stent for deployment in a blood vessel.

Abstract: A medical device includes an expandable element for location in a blood vessel. The expandable element is movable between a collapsed configuration and an expanded configuration. In the expanded configuration, at least a part of a longitudinal axis of the expandable element is curved in three-dimensional space. The medical device can be stent deployment device which includes an elongate catheter shaft and an inflatable balloon.

Abstract: A stent deployment device comprises an elongate catheter shaft (2), and an inflatable balloon (3). The inflatable balloon (3) is movable between a collapsed configuration and an expanded configuration. In the expanded configuration part of the longitudinal axis of the balloon (3) is curved in three-dimensional space, and part of the balloon (3) is helically shaped. A stent (6) is movable from a collapsed delivery configuration to a partially expanded intermediate configuration, and subsequently from the intermediate configuration to a fully expanded deployed configuration. In the delivery configuration the longitudinal axis of the stent (6) is straight. The longitudinal axis of the stent (6) may be straight or curved in three-dimensional space in the intermediate configuration. In the deployed configuration the longitudinal axis of the stent (6) is curved in three-dimensional space. The balloon (3) in the expanded configuration exerts force on the stent (6).

Abstract: A stent (1) for deployment in a blood vessel which is movable between an unloaded straight cylindrical state and a loaded curved state. The stent (1) is bendable between a first loaded configuration when the blood vessel is in the unloaded state, and a second loaded configuration when the blood vessel is in the loaded state. The stent (1) has an unloaded configuration which is intermediate the first loaded configuration and the second loaded configuration. Because of the unloaded configuration of the stent (1), the degrees of deformation which the stent (1) undergoes are minimised leading to minimised strains, increased fatigue life, and reduced risk of fracture.

Abstract: An inflatable restraint assembly includes an air bag door and chute. The air bag door includes at least one fastener integrally-formed with the air bag door. The chute is adapted to receive the at least one fastener to effect an interlock for retaining the air bag door to the chute. A method for manufacturing the inflatable restraint assembly is also disclosed. A method for assembling the inflatable restraint assembly is also disclosed.

Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio.

Abstract: An inflatable restraint assembly includes an air bag door and chute. The air bag door includes at least one fastener integrally-formed with the air bag door. The chute is adapted to receive the at least one fastener to effect an interlock for retaining the air bag door to the chute. A method for manufacturing the inflatable restraint assembly is also disclosed. A method for assembling the inflatable restraint assembly is also disclosed.

Abstract: A cross car duct for use in an instrument panel assembly of an automotive vehicle includes an upper beam of one piece molded plastic extending longitudinally between opposing A-pillars of the vehicle. The cross car duct also includes a lower beam of one piece molded plastic attached to the upper beam and extending longitudinally between the A-pillars. A magnesium steering column support for supporting conventional steering components on the cross car duct is fixedly secured to the upper beam. The upper beam includes a plurality of air ducts and the lower beam includes a plurality of air openings aligned with the air ducts for passing air through the beams. The lower beam also includes a housing for supporting an HVAC module. The cross car duct further includes a plurality of integrated mode doors and actuators operatively connected to the housing of the lower beam for actuation between an open position spaced from the air openings and a closed position covering the air openings in the lower beam.

Abstract: A cross car duct for use in an instrument panel assembly of an automotive vehicle includes an upper beam of one piece molded plastic extending longitudinally between opposing A-pillars of the vehicle. The cross car duct also includes a lower beam of one piece molded plastic attached to the upper beam and extending longitudinally between the A-pillars. A magnesium steering column support for supporting conventional steering components on the cross car duct is fixedly secured to the upper beam. The upper beam includes a plurality of air ducts and the lower beam includes a plurality of air openings aligned with the air ducts for passing air through the beams. The lower beam also includes a housing for supporting an HVAC module. The cross car duct further includes a plurality of integrated mode doors and actuators operatively connected to the housing of the lower beam for actuation between an open position spaced from the air openings and a closed position covering the air openings in the lower beam.

Abstract: The cargo management device (24) includes a frame having a pair of parallel support beams extending between a first and second end. The frame may be made of multiple frame portions that are attached to each other using hinges or other like mechanisms. The frame also has a plurality of cross beams extending between the pair of parallel support beams. A plurality of securing devices allows articles to be attached or secured to the frame between the frame and the vehicle floor (18). The cargo management device (24) also includes an attachment mechanism attaching the frame to the two opposing sidewalls (12,14) of the motor vehicle spaced apart from the vehicle floor (18) so that the articles being stored may he suspended from the frame or organized using netting and the like.

Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio.

Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders.